Regulatory Pathways for Biomarker Qualification
Regulatory Pathways for Biomarker Qualification Navigating Regulatory Routes for Biomarker Qualification in Drug Development Why Biomarker Qualification Matters Biomarkers are vital tools in modern clinical trials, enabling early detection, risk stratification, pharmacodynamic monitoring, and surrogate endpoint development. However, before a biomarker can be used broadly in regulatory submissions, it must undergo a formal qualification process….
Read More “Regulatory Pathways for Biomarker Qualification” »